News & Updates
Showing Pharmacy articles
Showing
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
Otilimab for RA disappoints in ContRAst 3
In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.
Treating hypertension helps lower dementia risk in older adults
Older adults with hypertension who are on blood pressure (BP)-lowering medications are better protected against dementia than those with untreated hypertension, and this is true across all ages in late life, according to an individual participant data meta-analysis.
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.
